share_log

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Path To Profitability

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Path To Profitability

Travere Therapeutics, Inc.(納斯達克:TVTX)實現盈利的路徑
Simply Wall St ·  01/11 13:16

We feel now is a pretty good time to analyse Travere Therapeutics, Inc.'s (NASDAQ:TVTX) business as it appears the company may be on the cusp of a considerable accomplishment. Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. With the latest financial year loss of US$376m and a trailing-twelve-month loss of US$349m, the US$1.7b market-cap company alleviated its loss by moving closer towards its target of breakeven. As path to profitability is the topic on Travere Therapeutics' investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

我們認爲現在分析Travere Therapeutics, Inc.(納斯達克:TVTX)的業務是個不錯的時機,因爲該公司似乎即將取得重大成就。Travere Therapeutics, Inc.是一家生物製藥公司,專注於識別、開發和提供針對罕見腎臟和代謝疾病的療法。最近的財年公司虧損了37600萬美金,過去十二個月的虧損爲34900萬美金,這家市值17億美元的公司通過向盈虧平衡目標邁進,減輕了其損失。考慮到盈利能力是Travere Therapeutics投資者關注的話題,我們決定評估市場情緒。在這篇文章中,我們將討論公司增長的預期以及分析師預計其盈利的時間。

According to the 15 industry analysts covering Travere Therapeutics, the consensus is that breakeven is near. They expect the company to post a final loss in 2025, before turning a profit of US$26m in 2026. Therefore, the company is expected to breakeven just over a year from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 63% is expected, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.

根據覆蓋Travere Therapeutics的15位行業分析師的意見,大家一致認爲盈虧平衡點即將到來。他們預計公司在2025年將出現最終虧損,然後在2026年實現2600萬美金的盈利。因此,預計公司將在一年多之後達到盈虧平衡。爲了滿足這一盈虧平衡日期,我們計算了公司必須每年增長的速度。結果顯示,預計年均增長率爲63%,這表明分析師對公司的信心很高。如果業務以較慢的速度增長,將在預計的時間之後實現盈利。

big
NasdaqGM:TVTX Earnings Per Share Growth January 11th 2025
納斯達克GM:TVTX 每股收益增長 2025年1月11日

Given this is a high-level overview, we won't go into details of Travere Therapeutics' upcoming projects, but, bear in mind that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

由於這是一個高層次的概述,我們將不詳細介紹Travere Therapeutics即將推出的項目,但請記住,一般來說,生物技術公司依據產品開發階段不同,現金流週期不規則。因此,高增長率並不罕見,尤其是當公司處於投資期時。

Before we wrap up, there's one issue worth mentioning. Travere Therapeutics currently has negative equity on its balance sheet. This can sometimes arise from accounting methods used to deal with accumulated losses from prior years, which are viewed as liabilities carried forward until it cancels out in the future. Oftentimes, losses exist only on paper but other times, it can be a red flag.

在結束之前,有一個問題值得提及。Travere Therapeutics目前在其資產負債表上有負資產。這有時可能是由於用於處理前幾年累計虧損的會計方法造成的,這些虧損在未來被視爲負債。通常,虧損只存在於賬面上,但有時,這可能是個警告信號。

Next Steps:

下一步:

There are key fundamentals of Travere Therapeutics which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Travere Therapeutics, take a look at Travere Therapeutics' company page on Simply Wall St. We've also put together a list of pertinent factors you should look at:

Travere Therapeutics的關鍵基本面在本文中沒有涵蓋,但我們必須再次強調,這只是一個基本概述。要想更全面地了解Travere Therapeutics,請查看Travere Therapeutics在Simply Wall ST上的公司頁面。我們還整理了一份您應該關注的相關因素清單:

  1. Valuation: What is Travere Therapeutics worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Travere Therapeutics is currently mispriced by the market.
  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Travere Therapeutics's board and the CEO's background.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
  1. 估值:今天Travere Therapeutics值多少錢?未來的增長潛力是否已經反映在價格中?我們免費研究報告中的內在價值信息圖幫助可視化Travere Therapeutics當前是否被市場錯定。
  2. 管理團隊:經驗豐富的管理團隊掌舵提高了我們對業務的信心——看看誰在Travere Therapeutics的董事會以及首席執行官的背景。
  3. 其他高表現股票:是否還有其他股票提供更好的前景和經過驗證的業績?在這裏查看我們這些優秀股票的免費列表。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall ST的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中均沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論

    聲明

    本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。